adalimumab-adbm (Cyltezo) vs Hemay007

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT02871635 · Phase 3 · completed

This was a randomized, double-blind trial against the reference adalimumab product, with a validated Crohn's disease activity score as the primary endpoint. Clinical response at week 4 was similar in both groups (risk ratio 0.945, 90% CI 0.870 to 1.028), within the prespecified non-inferiority margin, and 147 people were randomized against a planned 130.

Hanauer et al. (Lancet Gastroenterol Hepatol, 2021; PMID 34388360) report different figures for this outcome, clinical response in 61 of 68 patients (90%) with BI 695501 and 68 of 72 (94%) with the reference product, because the registry figures are model-based least-squares means.

Reported efficacy

Percentage of Patients With a Clinical Response (CDAI Decrease of ≥70 Compared With Baseline) at Week 4: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol). (met)

Result source: NCT02871635

Hemay007

Developed by Tianjin Hemay Pharmaceutical

Phase 1 in Crohn's Diseasesmall molecule
Weak signal

NCT02603185 · Phase 1 · status unknown

This is a randomized, double-blind, placebo-controlled early-phase safety and pharmacokinetics study conducted in healthy volunteers rather than in patients with the target condition, with adverse-event monitoring as its primary endpoint rather than a measure of disease benefit. No results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "Adverse events assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)Hemay007
Clinical remission (induction)—Not reported—Not reported
Endoscopic response (induction)—Not reported—Not reported
Clinical remission (maintenance)68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT02871635—Not reported
Endoscopic response (maintenance)—Not reported—Not reported

Clinical remission (induction)

adalimumab-adbm (Cyltezo)
—Not reported
Hemay007
—Not reported

Endoscopic response (induction)

adalimumab-adbm (Cyltezo)
—Not reported
Hemay007
—Not reported

Clinical remission (maintenance)

adalimumab-adbm (Cyltezo)
68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT02871635
Hemay007
—Not reported

Endoscopic response (maintenance)

adalimumab-adbm (Cyltezo)
—Not reported
Hemay007
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Hemay007: no structured comparison results are available for Crohn's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adbm (Cyltezo): 4 of 4 rows · Hemay007: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-adbm (Cyltezo)
Dropout rate
25%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Discontinued due to AEs
5.6%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Serious AEs
—BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
8.3%BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
2.8%BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Most frequent reported AEs
arthralgia 8.3%
respiratory tract infection 6.9%
crohn's disease 5.6%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
nasopharyngitis 6.9%
weight increased 4.2%
arthralgia 2.8%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-adbm (Cyltezo)

CDAI ≥ 70 88% (n=68) vs 93.1% (n=72) Humira EU @ 4wk
responder rate · % of participants
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
87.4% (n=68) vs 87.4% (n=72) Humira EU @ 24wk
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Clinical Remission 68.6% (n=68) vs 76.2% (n=72) Humira EU @ 24wk
responder rate · % of participants
NCT02871635 · Phase 3 · Crohn's Disease · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-adbm (Cyltezo)'s landscape · Hemay007's landscape